Pfizer: Urinary Bladder Neoplasms trials
The registry lists 24 Urinary Bladder Neoplasms studies with Pfizer as lead sponsor. 6 are open to participants now and 10 have results posted.
Phase 1 13Phase 2 7Phase 3 3No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different HistologiesNot yet recruitingNCT07897669
- Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerRecruitingNCT07421700Phase 1/2
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder CancerRecruitingNCT07206225Phase 1
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Phase 1
- A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2RecruitingNCT04879329Phase 2
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1
- Study of PF-07263689 in Participants With Selected Advanced Solid TumorsTerminatedNCT05061537Phase 1Results posted
- A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMACompletedNCT04822350Results posted
- A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerActive, not recruitingNCT04165317Phase 3Results posted
- A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)TerminatedNCT03472560Phase 2Results posted
- Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedNCT03245736Phase 2Results posted
- A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)CompletedNCT02603432Phase 3Results posted
- A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)TerminatedNCT02554812Phase 1/2Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02552121Phase 1/2Results posted
- Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566CompletedNCT02315066Phase 1Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02001623Phase 1/2Results posted
- A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerTerminatedNCT06580938Phase 1
- Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active, not recruitingNCT05911295Phase 3
- HER2 and LA/mUC: A Multi-country Chart Review Cohort StudyCompletedNCT05902494
- A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder CancerTerminatedNCT05699135
- A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial CancerTerminatedNCT05568407
- PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)WithdrawnNCT05259397Phase 1
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
- A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsTerminatedNCT02952989Phase 1